ReviewDiabetes & metabolic syndrome
Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19).
Review in Diabetes & metabolic syndrome. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- The use of statins was associated with reduced COVID-19 mortality: a systematic review and meta-analysis.Annals of medicine · 2021 · on this mapPooled it
- Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies.Diabetes & metabolism · 2021 · on this mapPooled it
- In Vitro Investigation of Statin Effects on Genes Associated with Severe COVID-19 in Cancerous and Non-Cancerous Cells.Biomedicines · 2025Article
- Mechanisms and Nanomedicine Interventions of Acute Lung Injury Induced by Intestinal Ischemia-Reperfusion: A Mini Review.International journal of nanomedicine · 2025Review
- Review
- Association of statin use with outcomes of patients admitted with COVID-19: an analysis of electronic health records using superlearner.BMC infectious diseases · 2023Article
- Statins Use in Patients with Cardiovascular Diseases and COVID-19 Outcomes: An Italian Population-Based Cohort Study.Journal of clinical medicine · 2022Article
- Phenotypical and Functional Alteration of γδ T Lymphocytes in COVID-19 Patients: Reversal by Statins.Cells · 2022Article
- In Vitro Evidence of Statins' Protective Role against COVID-19 Hallmarks.Biomedicines · 2022Article
- Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.Signal transduction and targeted therapy · 2022Review
- Protective effects of statins on COVID-19 risk, severity and fatal outcome: a nationwide Swedish cohort study.Scientific reports · 2022Article
- The effects of SARS-CoV-2 infection on modulating innate immunity and strategies of combating inflammatory response for COVID-19 therapy.Journal of biomedical science · 2022Review
- Acute myocardial injury in patients with COVID-19: Possible mechanisms and clinical implications.World journal of clinical cases · 2022Review
- Biological Actions, Implications, and Cautions of Statins Therapy in COVID-19.Frontiers in nutrition · 2022Review
- Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality.International reviews of immunology · 2022Article
- Impact of Metabolic Risk Factors on COVID-19 Clinical Outcomes: An Extensive Review.Current cardiology reviews · 2022Review
- An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2021Review
- Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease.Expert opinion on pharmacotherapy · 2021Review
- DCcov: Repositioning of drugs and drug combinations for SARS-CoV-2 infected lung through constraint-based modeling.iScience · 2021Article
- Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave.Pharmacoepidemiology and drug safety · 2021Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsMorbidity and mortality from coronavirus disease 2019 (COVID-19) is higher among people with diabetes mellitus (DM), hypertension, and cardiovascular disease (CVD). Statins are used in the majority of people with DM and CVD. This mini-review discusses the current understanding of benefit-risk ratio of use of statins in COVID-19.
methodsWe searched PubMed database using specific keywords related to our aims till June 12, 2020. Full text of relevant articles published in English language were retrieved and reviewed.
resultsStatins, with their immunomodulatory, anti-inflammatory, anti-thrombotic, and anti-oxidant properties, have the potential to reduce severity of lung injury in, and mortality from, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) infections. Statin-induced upregulation of angiotensin-converting enzyme-2 (ACE2) has the potential to reduce lung injury from excess angiotensin II. By disrupting lipid rafts, statins have the potential to reduce viral entry into cells. However, benefit-risk ratio of its complex interaction with MYD88 gene expression on outcomes in COVID-19, and the putative role of low serum LDL cholesterol in increasing severity of SARS-CoV2 infection need further clarification.
conclusionsPeople with COVID-19, who are already on statins for an underlying co-morbid condition, should continue on it unless there are specific contraindications. De-novo use of statins in people with COVID-19 with no underlying co-morbidity might be beneficial but awaits substantiation in clinical trials; till that time, de novo use of statins in COVID 19 should be limited to a clinical trial setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.